Akari Therapeutics Shares Surge Over 100% on Breakthrough Data
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 22 2026
0mins
Source: NASDAQ.COM
- Breakthrough Clinical Data: Akari Therapeutics reported that its antibody-drug conjugate AKTX-101 demonstrated synergistic anti-cancer activity when combined with KRAS inhibitor Adagrasib in KRAS-mutated pancreatic cancer models, indicating a potentially powerful combination therapy.
- Efficacy Validation: AKTX-101 achieved Bliss synergy scores exceeding 10 in KRAS-mutant pancreatic cancer cell lines, while traditional TROP2 ADC combinations showed antagonistic effects, underscoring the unique biological mechanism of Akari's PH1 payload.
- Clinical Trial Plans: Akari has initiated IND-enabling studies for AKTX-101 and aims to start its first-in-human clinical trial by mid-2027, showcasing the company's forward-looking strategy in cancer treatment.
- Strong Market Reaction: In pre-market trading, AKTX shares surged from $5.14 to $10.57, reflecting an over 100% increase, indicating high investor confidence and recognition of the new data.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AKTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AKTX
Wall Street analysts forecast AKTX stock price to fall
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 22.050
Low
1.00
Averages
3.33
High
7.00
Current: 22.050
Low
1.00
Averages
3.33
High
7.00
About AKTX
Akari Therapeutics, Plc is a biotechnology company developing precision bifunctional antibody drug conjugates (ADC) for the treatment of cancer. Utilizing its ADC discovery platform, it generates bifunctional ADC candidates and optimizes them based on the desired application to target a range of cancers. Its lead candidate, AKTX-101, targets the TROP2 receptor on cancer cells, and with a proprietary linker, delivers its novel PH1 payload directly into the tumor. PH1 is a novel bifunctional payload that is designed to disrupt RNA splicing within cancer cells, inducing tumor-specific cell death while generating immunostimulatory effects and minimizing off-target toxicity. Its pipeline includes AKTX-101 and AKTX-102, a discovery-stage ADC that pairs PH1 with an undisclosed target antibody. It is pursuing research on two additional novel payloads, such as PH5 and PH6. It also has an ADC Platform for oncology and PHP-303 program for genetic disease, liver disease and inflammation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
SciSparc Receives Approval to Acquire Stake in Israeli Tech Firm
- Acquisition Approval: SciSparc Ltd. (SPRC) received regulatory approval from the TSX Venture Exchange for its subsidiary NeuroThera Labs to acquire approximately 54% of CliniQuantum, valued at about $9.46 million, which is expected to enhance its competitive edge in clinical trial data analysis.
- Stock Surge: SPRC's shares soared nearly 140% to close at $10.55 on Thursday, reflecting strong market enthusiasm for its acquisition plans, which may attract further investor interest in its future growth prospects.
- Ebola Testing Progress: Co-Diagnostics Inc. (CODX) saw its stock rally over 50% for the third consecutive day amid the Ebola outbreak, indicating the effectiveness of its PCR assay strategy, which is likely to bolster the company's influence in public health.
- Clinical Trial Initiation: MiNK Therapeutics (INKT) dosed its first patient in a randomized phase 2 trial for acute lung injury, leading to an 18% stock increase, and this advancement could provide crucial data support for its future treatment options, strengthening its market position.
See More
U.S. Stocks Reach Record Highs as Investor Optimism Grows
- Strong Market Performance: The S&P 500 rose by 0.6%, the Nasdaq 100 increased by 0.6%, and the Dow Jones inched up by 0.1%, all hitting record highs, reflecting investor optimism about future economic recovery.
- Consumer Spending Recovery: Adjusted for inflation, consumer spending increased by 0.1% in April after a 1.6% rise in March, indicating a gradual restoration of consumer confidence that could drive economic growth.
- International Situation Impact: Market sentiment improved following news of a 60-day memorandum of understanding between U.S. and Iranian negotiators, leading to a pullback in oil prices to around $89 per barrel, highlighting investor concerns over geopolitical risks.
- Strong ETF Performance: The SPDR S&P 500 ETF and Invesco QQQ Trust rose approximately 0.6% and 1% respectively, reflecting strong investor interest in tech and consumer stocks, further propelling the market upward.
See More
Akari Therapeutics Shows Promising Cancer Treatment Progress
- Promising Preclinical Data: CEO of Akari Therapeutics highlighted that the ADC platform showed encouraging results in pancreatic cancer models with KRAS mutations, indicating its potential to redefine treatment for difficult-to-treat KRAS-driven cancers, particularly where current options are limited.
- Funding for Trials: The company announced a $5.5 million private financing deal to support the Phase 1 clinical trial of AKTX-101, which is set to begin by mid-2027, ensuring necessary funding for advancing its clinical research efforts.
- Stock Surge: Following the CEO's remarks on the ADC platform's potential, Akari's shares surged nearly 50% on Thursday, reflecting strong market enthusiasm ahead of an upcoming oncology conference and investor confidence in the company's future prospects.
- Bullish Market Sentiment: Retail sentiment on Stocktwits for AKTX remained in the 'extremely bullish' territory over the past 24 hours, with high message volumes indicating expectations of a potential buyout by big pharma, further fueling the stock's upward momentum.
See More
Akari Therapeutics Showcases Promising ASCO Data on AKTX-101
- ASCO Data Highlight: Akari Therapeutics' first ASCO abstract acceptance showcases the synergy of AKTX-101 with a KRAS inhibitor in KRAS-mutated pancreatic cancer models, indicating its potential to transform treatment options for difficult-to-treat cancers.
- Innovative Drug Platform: AKTX-101 employs a unique PH1 payload targeting the Trop2 receptor on cancer cells, demonstrating significant anti-tumor activity and prolonged survival, particularly in combination with checkpoint inhibitors, highlighting its synergistic effects.
- Clinical Trial Plans: The company aims to initiate its first-in-human clinical trial for AKTX-101 by mid-2027, marking a critical milestone in its product development that is expected to attract investor interest and potentially drive stock price increases.
- Broad Market Prospects: With the rising demand for treatments targeting KRAS-driven tumors, Akari's innovative drug platform is poised to capture a significant share in the rapidly evolving ADC market, addressing substantial unmet medical needs.
See More
Biotech Stocks Surge with Akari Leading the Rally
- Akari Therapeutics Surge: Akari Therapeutics (AKTX) soared over 255% on Friday, marking its second consecutive day of gains following the announcement of breakthrough preclinical data for its drug AKTX-101, which demonstrated synergistic effects in KRAS-mutated pancreatic cancer models, highlighting significant advancements in oncology.
- MetaVia Clinical Progress: MetaVia Inc. (MTVA) rose over 34% on Friday as the company advances its DA-1726 in a Phase 1 trial for treating cardiometabolic diseases, with an end-of-Phase 2 meeting with the FDA planned, indicating strong potential in the cardiometabolic sector.
- GeoVax Vaccine Development: GeoVax Labs Inc. (GOVX) increased over 32% on Friday amid a growing Ebola outbreak, as the company progresses its vaccine development against Ebola and Marburg viruses, with a pivotal Phase 3 study of its GEO-MVA candidate set to begin in Q4 2026, underscoring its role in addressing public health emergencies.
- Polyrizon Clinical Agreement: Polyrizon Ltd. (PLRZ) gained over 20% on Friday after signing its first Clinical Trial Agreement for NASARIX Allergy Blocker, aimed at treating seasonal allergic rhinitis, marking a significant step towards initiating its first-in-human clinical study and showcasing its innovative potential in biotechnology.
See More
Biotech Sector Attracts Investor Attention Amid Innovation
- Investor Enthusiasm: The biotech sector is attracting significant speculative capital due to innovations in next-generation oncology, metabolic diseases, and CNS therapy platforms, indicating strong market interest that could drive stock prices of related companies higher.
- Akari Therapeutics New Data: Akari Therapeutics' ADC candidate AKTX-101 demonstrated synergistic activity in KRAS-mutated pancreatic cancer models, further expanding the potential of its RNA spliceosome-modulating payload platform, which may open new market opportunities for the company.
- NeOnc Technologies Analyst Focus: NeOnc Technologies is gaining attention for its neuro-oncology platform targeting the blood-brain barrier, with multiple analysts issuing “Buy” ratings, which is expected to enhance the company's visibility ahead of anticipated clinical updates.
- MetaVia Research Findings: MetaVia's GPR119 agonist vanoglipel has shown anti-fibrotic potential in new research, indicating its promise in treating metabolic dysfunction-associated steatohepatitis, which may attract further investor interest as clinical data develops.
See More
SciSparc Receives Approval to Acquire Stake in Israeli Tech Firm
- Acquisition Approval: SciSparc Ltd. (SPRC) received regulatory approval from the TSX Venture Exchange for its subsidiary NeuroThera Labs to acquire approximately 54% of CliniQuantum, valued at about $9.46 million, which is expected to enhance its competitive edge in clinical trial data analysis.
- Stock Surge: SPRC's shares soared nearly 140% to close at $10.55 on Thursday, reflecting strong market enthusiasm for its acquisition plans, which may attract further investor interest in its future growth prospects.
- Ebola Testing Progress: Co-Diagnostics Inc. (CODX) saw its stock rally over 50% for the third consecutive day amid the Ebola outbreak, indicating the effectiveness of its PCR assay strategy, which is likely to bolster the company's influence in public health.
- Clinical Trial Initiation: MiNK Therapeutics (INKT) dosed its first patient in a randomized phase 2 trial for acute lung injury, leading to an 18% stock increase, and this advancement could provide crucial data support for its future treatment options, strengthening its market position.
See More
U.S. Stocks Reach Record Highs as Investor Optimism Grows
- Strong Market Performance: The S&P 500 rose by 0.6%, the Nasdaq 100 increased by 0.6%, and the Dow Jones inched up by 0.1%, all hitting record highs, reflecting investor optimism about future economic recovery.
- Consumer Spending Recovery: Adjusted for inflation, consumer spending increased by 0.1% in April after a 1.6% rise in March, indicating a gradual restoration of consumer confidence that could drive economic growth.
- International Situation Impact: Market sentiment improved following news of a 60-day memorandum of understanding between U.S. and Iranian negotiators, leading to a pullback in oil prices to around $89 per barrel, highlighting investor concerns over geopolitical risks.
- Strong ETF Performance: The SPDR S&P 500 ETF and Invesco QQQ Trust rose approximately 0.6% and 1% respectively, reflecting strong investor interest in tech and consumer stocks, further propelling the market upward.
See More
Akari Therapeutics Shows Promising Cancer Treatment Progress
- Promising Preclinical Data: CEO of Akari Therapeutics highlighted that the ADC platform showed encouraging results in pancreatic cancer models with KRAS mutations, indicating its potential to redefine treatment for difficult-to-treat KRAS-driven cancers, particularly where current options are limited.
- Funding for Trials: The company announced a $5.5 million private financing deal to support the Phase 1 clinical trial of AKTX-101, which is set to begin by mid-2027, ensuring necessary funding for advancing its clinical research efforts.
- Stock Surge: Following the CEO's remarks on the ADC platform's potential, Akari's shares surged nearly 50% on Thursday, reflecting strong market enthusiasm ahead of an upcoming oncology conference and investor confidence in the company's future prospects.
- Bullish Market Sentiment: Retail sentiment on Stocktwits for AKTX remained in the 'extremely bullish' territory over the past 24 hours, with high message volumes indicating expectations of a potential buyout by big pharma, further fueling the stock's upward momentum.
See More
Akari Therapeutics Showcases Promising ASCO Data on AKTX-101
- ASCO Data Highlight: Akari Therapeutics' first ASCO abstract acceptance showcases the synergy of AKTX-101 with a KRAS inhibitor in KRAS-mutated pancreatic cancer models, indicating its potential to transform treatment options for difficult-to-treat cancers.
- Innovative Drug Platform: AKTX-101 employs a unique PH1 payload targeting the Trop2 receptor on cancer cells, demonstrating significant anti-tumor activity and prolonged survival, particularly in combination with checkpoint inhibitors, highlighting its synergistic effects.
- Clinical Trial Plans: The company aims to initiate its first-in-human clinical trial for AKTX-101 by mid-2027, marking a critical milestone in its product development that is expected to attract investor interest and potentially drive stock price increases.
- Broad Market Prospects: With the rising demand for treatments targeting KRAS-driven tumors, Akari's innovative drug platform is poised to capture a significant share in the rapidly evolving ADC market, addressing substantial unmet medical needs.
See More
Biotech Stocks Surge with Akari Leading the Rally
- Akari Therapeutics Surge: Akari Therapeutics (AKTX) soared over 255% on Friday, marking its second consecutive day of gains following the announcement of breakthrough preclinical data for its drug AKTX-101, which demonstrated synergistic effects in KRAS-mutated pancreatic cancer models, highlighting significant advancements in oncology.
- MetaVia Clinical Progress: MetaVia Inc. (MTVA) rose over 34% on Friday as the company advances its DA-1726 in a Phase 1 trial for treating cardiometabolic diseases, with an end-of-Phase 2 meeting with the FDA planned, indicating strong potential in the cardiometabolic sector.
- GeoVax Vaccine Development: GeoVax Labs Inc. (GOVX) increased over 32% on Friday amid a growing Ebola outbreak, as the company progresses its vaccine development against Ebola and Marburg viruses, with a pivotal Phase 3 study of its GEO-MVA candidate set to begin in Q4 2026, underscoring its role in addressing public health emergencies.
- Polyrizon Clinical Agreement: Polyrizon Ltd. (PLRZ) gained over 20% on Friday after signing its first Clinical Trial Agreement for NASARIX Allergy Blocker, aimed at treating seasonal allergic rhinitis, marking a significant step towards initiating its first-in-human clinical study and showcasing its innovative potential in biotechnology.
See More
Biotech Sector Attracts Investor Attention Amid Innovation
- Investor Enthusiasm: The biotech sector is attracting significant speculative capital due to innovations in next-generation oncology, metabolic diseases, and CNS therapy platforms, indicating strong market interest that could drive stock prices of related companies higher.
- Akari Therapeutics New Data: Akari Therapeutics' ADC candidate AKTX-101 demonstrated synergistic activity in KRAS-mutated pancreatic cancer models, further expanding the potential of its RNA spliceosome-modulating payload platform, which may open new market opportunities for the company.
- NeOnc Technologies Analyst Focus: NeOnc Technologies is gaining attention for its neuro-oncology platform targeting the blood-brain barrier, with multiple analysts issuing “Buy” ratings, which is expected to enhance the company's visibility ahead of anticipated clinical updates.
- MetaVia Research Findings: MetaVia's GPR119 agonist vanoglipel has shown anti-fibrotic potential in new research, indicating its promise in treating metabolic dysfunction-associated steatohepatitis, which may attract further investor interest as clinical data develops.
See More
